Ranbaxy won FDA approval to produce a long-delayed generic version of Novartis's blockbuster blood-pressure drug Diovan, improving the Indian company's prospects after years of regulatory problems.
via WSJ.com: US Business http://ift.tt/1qNj3N1
via WSJ.com: US Business http://ift.tt/1qNj3N1
Nessun commento:
Posta un commento